NASDAQ:ANAB - AnaptysBio Stock Price, Forecast & News

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio Inc (NASDAQ:ANAB) posted its quarterly earnings results on Friday, November, 8th. The biotechnology company reported ($1.15) EPS for the quarter, missing the Zacks' consensus estimate of ($1.09) by $0.06. During the same period last year, the business posted ($0.66) earnings per share. View AnaptysBio's Earnings History.

AnaptysBio is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AnaptysBio.

9 brokers have issued 12 month price objectives for AnaptysBio's shares. Their forecasts range from $12.00 to $140.00. On average, they expect AnaptysBio's stock price to reach $79.25 in the next twelve months. This suggests a possible upside of 462.5% from the stock's current price. View Analyst Price Targets for AnaptysBio.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AnaptysBio.

Media stories about ANAB stock have been trending somewhat negative on Tuesday, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AnaptysBio earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for AnaptysBio.

AnaptysBio saw a increase in short interest in January. As of January 15th, there was short interest totalling 3,970,000 shares, an increase of 14.7% from the December 31st total of 3,460,000 shares. Based on an average daily volume of 950,100 shares, the days-to-cover ratio is currently 4.2 days. Currently, 16.3% of the company's shares are short sold. View AnaptysBio's Current Options Chain.

Some companies that are related to AnaptysBio include Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Innoviva (INVA), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), TG Therapeutics (TGTX), Esperion Therapeutics (ESPR), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Endo International (ENDP), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN) and IGM Biosciences (IGMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Editas Medicine (EDIT), Baidu (BIDU), Alibaba Group (BABA), Baozun (BZUN), IQIYI (IQ), Momo (MOMO), NVIDIA (NVDA), AbbVie (ABBV), bluebird bio (BLUE) and Illumina (ILMN).

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.19%), Virginia Retirement Systems ET AL (0.05%) and Valeo Financial Advisors LLC (0.02%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria, Marco Londei and Nicholas Lydon. View Institutional Ownership Trends for AnaptysBio.

ANAB stock was purchased by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, California Public Employees Retirement System and Valeo Financial Advisors LLC. View Insider Buying and Selling for AnaptysBio.

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANAB stock can currently be purchased for approximately $14.09.

AnaptysBio has a market capitalization of $382.30 million and generates $5 million in revenue each year. The biotechnology company earns $-61,660,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.View Additional Information About AnaptysBio.

The official website for AnaptysBio is http://www.anaptysbio.com/.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]